Identifying inflammatory phenotypes to target mechanism-specific treatments in sepsis

A clinical trial by Leventogiannis et al.(1) suggests that ferritin and HLA-DR monocyte receptor expression can identify septic patients with macrophage-activation-like syndrome (MALS), or immunoparalysis, and that targeting IL-1ra treatment with this strategy may improve outcomes.

Detalles Bibliográficos
Autores principales: Gómez, Hernando, Anderko, Renee R., Carcillo, Joseph A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Preview
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9729868/
https://www.ncbi.nlm.nih.gov/pubmed/36384087
http://dx.doi.org/10.1016/j.xcrm.2022.100823
Descripción
Sumario:A clinical trial by Leventogiannis et al.(1) suggests that ferritin and HLA-DR monocyte receptor expression can identify septic patients with macrophage-activation-like syndrome (MALS), or immunoparalysis, and that targeting IL-1ra treatment with this strategy may improve outcomes.

Ejemplares similares